FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) Supplemental New Drug Application (sNDA) to include data for the Reduction of COPD Exacerbations and Hospitalizations - Business Wire

FDA Approves TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) Supplemental New Drug Application (sNDA) to include data for the Reduction of COPD Exacerbations and Hospitalizations  Business Wire

MORRISVILLE, N.C.--(BUSINESS WIRE)--Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), announced today that the US Food and Drug ...



Comments

Popular posts from this blog

“Stem cells: A possible treatment for severe respiratory failure, a COVID-19 complication - Mirage News” plus 1 more

“Screening for hearing loss in primary care - Contemporary Pediatrics” plus 1 more

“Evidence of cross-species filovirus transmission from bats to humans - EurekAlert” plus 2 more